Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
暂无分享,去创建一个
G. Salles | J. Zaucha | P. Reinke | H. Riess | E. W. Van Den Neste | A. Hüttmann | U. Dührsen | G. Verhoef | V. Leblond | M. Dreyling | V. Kliem | T. Tousseyn | S. Choquet | O. Gheysens | I. Hauser | M. Subklewe | F. Morschhauser | R. Trappe | D. Dierickx | I. Anagnostopoulos | P. Mollee | C. Tarella | H. Zimmermann | E. Van Den Neste
[1] T. Tousseyn,et al. How I treat posttransplant lymphoproliferative disorders. , 2015, Blood.
[2] G. Salles,et al. International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20‐Positive B Cell PTLD: Clues From the PTLD‐1 Trial , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[3] R. Trappe,et al. EBV and posttransplantation lymphoproliferative disease: what to do? , 2013, Hematology. American Society of Hematology. Education Program.
[4] H. Riess,et al. Early and late posttransplant lymphoproliferative disorder after lung transplantation--34 cases from the European PTLD Network. , 2013, Transplantation.
[5] J. Fishman,et al. Pneumocystis Pneumonia in Solid Organ Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[6] F. Andersohn,et al. Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS) , 2012, Pharmacoepidemiology and drug safety.
[7] G. Salles,et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. , 2012, The Lancet. Oncology.
[8] E. Anaissie,et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] Markus Loeffler,et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.
[10] J. Briones,et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease , 2007, Haematologica.
[11] B. Dörken,et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution , 2007, Annals of Hematology.
[12] U. Jäger,et al. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. , 2007, Haematologica.
[13] J. Bergerat,et al. Long‐term survival in post‐transplant lymphoproliferative disorders with a dose‐adjusted ACVBP regimen , 2006, British journal of haematology.
[14] R. Marcus,et al. Anthracycline-based Chemotherapy as First-line Treatment in Adults with Malignant Posttransplant Lymphoproliferative Disorder after Solid Organ Transplantation , 2006, Transplantation.
[15] A. López-Guillermo,et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.
[16] G. Salles,et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. , 2006, Blood.
[17] K. Olthoff,et al. Treatment of PTLD with Rituximab or Chemotherapy , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[18] B. Dörken,et al. Effect of Anti‐CD 20 Antibody Rituximab in Patients with Post‐Transplant Lymphoproliferative Disorder (PTLD) , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[19] D. Dunn,et al. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation , 2005, Cancer.
[20] E. Cesarman,et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. , 2005, Blood.
[21] B. Sander,et al. Posttransplant lymphoma—A single-center experience of 500 liver transplantations , 2004, Medical oncology.
[22] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[23] N. Brousse,et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Michler,et al. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide‐doxorubicin‐vincristine‐prednisone chemotherapy , 1993, Cancer.
[25] T. Starzl,et al. REVERSIBILITY OF LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN-STEROID THERAPY , 1984, The Lancet.